Magazine

Issue 3-2017

Download Issue 3-2017 (pdf)

Letter from the Editor
Magnus Gisslén

GLE/PIB and SOF/VEL/VOX: the final nails in the coffin of HCV?
Johannes Vermehren

Back in business - a resistance report from Rome
Anders Sönnerborg

Antiretroviral therapy in experienced patients at IAS 2017
José A Arribas

What is the point of Bictegravir?
Graeme Moyle

Notes 2017
Leo Flamholc

Issue 2-2017

Download Issue 2-2017 (pdf)

Letter from the Editor
Magnus Gisslén

ILC in Amsterdam
Per Lundblad

Satellite Symposiums
Per Lundblad

No entry
José A Arribas

TAF for hepatitis B: improved safety profile or just a clever marketing?
Johannes Vermehren

Which is the best statin for HIV patients?
Graeme Moyle

Notes 2017
Leo Flamholc

Issue 1-2017

Download Issue 1-2017 (pdf)

Letter from the Editor
Magnus Gisslén

HIV Drug Therapy Glasgow 2016
Per Lundblad

Satellite Symposiums at HIV Glasgow 2016
Per Lundblad

Reduced Drug Regimens at CROI 2017
José A Arribas

HBV Reactivation in Patients Receiving DAAs for HCV
Johannes Vermehren

More sleepless nights
Graeme Moyle

Should we encourage women to breastfeed?
Chloe Orkin and Laura Byrne

Notes 2017
Leo Flamholc

Issue 4-2016

Download Issue 4-2016 (pdf)

Letter from the Editor
Magnus Gisslén

HIV & HCV Nordic Conference 2016
Per Lundblad

Satellite symposiums at the Nordic HIV & Hepatitis Conference
Per Lundblad

Dual therapies with boosted protease inhibitor and lamivudine
José A Arribas

Retreatment of patients in whom prior DAA therapy has failed
Johannes Vermehren

Breaking up is hard to do
Graeme Moyle

"Ecological ART"- news from HIV Glasgow 2016
Christine Katlama

Notes 2016
Leo Flamholc

Issue 3-2016

Download Issue 3-2016 (pdf)

Letter from the Editor
Magnus Gisslén

A Franco/Chinese SIV/HIV vaccine endeavor
Sven Britton

PADDLE and LATTE. The future of
antiretroviral therapy?
José A Arribas

Two new combination therapies
approved for the treatment of hepatitis C
Johannes Vermeheren

What’s new with Integrase Inhibitors?
Graeme Moyle

What’s New About Antiretroviral
Strategies?
Christine Katlama

Notes 2016
Leo Flamholc

 

Issue 2-2016

Download Issue 2-2016 (pdf)

Letter from the Editor
Magnus Gisslén

Hepatitis at the International Liver Congress 2016
Per Lundblad

Switching with confidence: the value of resistance testing in proviral DNA
José R Arribas

Future DAAs for the treatment of chronic hepatitis C infection
Johannes Vermehren

Where now for CCR5 antagonists?
Graeme Moyle

Meeting on cure in Stockholm
Per Lundblad

Notes 2016
Leo Flamholc

Issue 1-2016

Download Issue 1-2016 (pdf)

Letter from the Editor
Magnus Gisslén

EACS Conference in Barcelona
Per Lundblad

Hot lines from CROI 2016 – New drugs, classes and approaches
Christine Katlama

Antiretroviral Therapy at CROI 2016: too Little too Latte
Jose’ R Arribas

Hepatitis C virus (HCV) genotype 3 - the last treatment challenge?
Johannes Vermehren

Can NNRTIs become preferred again?
Graeme Moyle

Satellite symposiums at EACS Conference
Per Lundblad

Dapivirine: Lord of the rings?
Graeme Moyle

CROI 2016
Per Lundblad

AASLD Virology News 2015
Leo Flamholc

Notes 2016
Leo Flamholc

Issue 4-2015

Download Issue 4-2015 (pdf)

Guest Editorial: Letter from the president, European AIDS Clinical Society
Manuel Battegay

EACS Guidelines 8.0: the big reduction
José R Arribas

Lighter Antiretroviral Therapy: what ’s new from european teams?
Christine Katlama

HIV and Hepatitis Nordic Conference 2015
Per Lundblad

Satellite Symposiums at the HIV and Hepatitis Nordic Conference
Per Lundblad

Doctor, I can’t sleep!
Graeme Moyle

Notes 2015
Leo Flamholc

Issue 3-2015

Download Issue 3-2015 (pdf)

Letter from the Editor
Magnus Gisslén

The 7th Gilead Nordic Summer HIV Meeting
Eva Nordin

Three clinical trials of antiretroviral therapy at IAS 2015
José Arribas

Now is the time to start
Graeme Moyle

Risk for hepatocellular cancer in patients with cured hepatitis C
Soo Aleman

When to start? The end of an endless question
Christine Katlama

Notes 2015
Leo Flamholc

Issue 2-2015

Download Issue 2-2015 (pdf)

Letter from the Editor
Magnus Gisslén

ILC in Vienna
Per Lundblad

Efavirenz: too much of a good thing?
Jose R Arribas

The new DHHS guidelines. Forgetting evidence, embracing opinion
Graeme Moyle

Topical Conferences

New drugs from new classes of drugs
Christine Katlama

Monitoring the persistent HIV reservoir in the era of HIV cure trials
Ward de Spiegelaere and Linos Vanderkerckhove

Symposium on the search for a cure
Per Lundblad

Banishing B - going beyond management
Per Lundblad

Conquering C - going beyond cure
Per Lundblad

The new landscape in management of HCV
Per Lundblad

Notes 2015
Leo Flamholc

Pages